Last reviewed 2026-04-23 · How we verify

Erenumab Dose 1

Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis.

Erenumab is a monoclonal antibody that blocks calcitonin gene-related peptide (CGRP), a neuropeptide involved in migraine pathogenesis. Used for Episodic migraine prevention, Chronic migraine prevention.

At a glance

Mechanism of action

CGRP is released during migraine attacks and contributes to pain signaling and neuroinflammation. By binding to and neutralizing CGRP, erenumab prevents its interaction with CGRP receptors on sensory neurons, thereby reducing migraine frequency and severity. This mechanism addresses a key biological pathway implicated in both episodic and chronic migraine.

Approved indications

• Episodic migraine prevention
• Chronic migraine prevention

Common side effects

• Injection site reactions
• Nasopharyngitis
• Upper respiratory tract infection
• Sinusitis
• Constipation

Key clinical trials

• Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action (PHASE4)
• Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (PHASE3)
• China HeadAche DIsorders RegiStry
• Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine (PHASE3)
• Screening Trial for Pain Relief in Schwannomatosis (STARFISH) (PHASE2)
• Galcanezumab for Vestibular Migraine (PHASE2)
• Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention (PHASE2)
• A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.